Tag Archives: NASH

Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

Can-Fite BioPharma Ltd. announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled “An A3 Adenosine Receptor Ligand for Use in Treating Ectopic Fat Accumulation”. This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite’s drug platform technology, to reduce liver fat particularly in patients with non-alcoholic steatohepatitis (NASH).
[Can-Fite BioPharma Ltd. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus

Scientists explore the latest relevant literature and discuss the ongoing therapeutic options for non-alcoholic fatty liver disease (NAFLD) focused on targeting intermediary metabolism, insulin resistance and type 2 diabetes mellitus (T2DM) to remedy the global health burden of these diseases.
[Nature Reviews Endocrinology]
Ferguson, D., & Finck, B. N. (2021). Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology, 1–12. https://doi.org/10.1038/s41574-021-00507-z Cite
Abstract
Bookmark

No account yet? Register

0
Share

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim and Zealand Pharma A/S announced that the US FDA has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).
[Boehringer Ingelheim, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Can-Fite to Initiate Phase IIb NASH Study with Its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. announced it has received clearance from the Israeli Ministry of Health to commence a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH.
[Can-Fite BioPharma Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

A Novel, Multitargeted Endogenous Metabolic Modulator Composition Impacts Metabolism, Inflammation, and Fibrosis in Nonalcoholic Steatohepatitis-Relevant Primary Human Cell Models

Researchers described a study of a novel EMM composition comprising five amino acids and an amino acid derivative (Leucine, Isoleucine, Valine, Arginine, Glutamine, and N-acetylcysteine [LIVRQNac]) and its systematic evaluation across multiple NASH-relevant primary human cell model systems, including hepatocytes, macrophages, and stellate cells.
[Scientific Reports]
Daou, N., Viader, A., Cokol, M., Nitzel, A., Chakravarthy, M. V., Afeyan, R., Tramontin, T., Marukian, S., & Hamill, M. J. (2021). A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Scientific Reports, 11(1), 11861. https://doi.org/10.1038/s41598-021-88913-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Pirfenidone Modifies Hepatic miRNAs Expression in a Model of MAFLD/NASH

Scientists evaluated modifications by prolonged-release pirfenidone on key hepatic miRNAs expression in a MAFLD/NASH model.
[Scientific Reports]
Escutia-Gutiérrez, R., Rodríguez-Sanabria, J. S., Monraz-Méndez, C. A., García-Bañuelos, J., Santos-García, A., Sandoval-Rodríguez, A., & Armendáriz-Borunda, J. (2021). Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Scientific Reports, 11(1), 11709. https://doi.org/10.1038/s41598-021-91187-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Infections at the Nexus of Metabolic-Associated Fatty Liver Disease

Investigator focus in particular on how infectious diseases, including coronavirus disease-19, hepatitis C, acquired immunodeficiency syndrome, peptic ulcer and periodontitis, exacerbate metabolic-associated fatty liver disease.
[Archives of Toxicology]
Boeckmans, J., Rombaut, M., Demuyser, T., Declerck, B., Piérard, D., Rogiers, V., De Kock, J., Waumans, L., Magerman, K., Cartuyvels, R., Rummens, J.-L., Rodrigues, R. M., & Vanhaecke, T. (2021). Infections at the nexus of metabolic-associated fatty liver disease. Archives of Toxicology. https://doi.org/10.1007/s00204-021-03069-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

XCR1+ Type 1 Conventional Dendritic Cells Drive Liver Pathology in Non-alcoholic Steatohepatitis

Researchers identified a significant pathology-associated increase in hepatic conventional dendritic cells (cDC) and further defined their source as non-alcoholic fatty liver disease-induced boost in cycling of cDC progenitors in the bone marrow.
[Nature Medicine]
Deczkowska, A., David, E., Ramadori, P., Pfister, D., Safran, M., At The, B., Giladi, A., Jaitin, D. A., Barboy, O., Cohen, M., Yofe, I., Gur, C., Shlomi-Loubaton, S., Henri, S., Suhail, Y., Qiu, M., Kam, S., Hermon, H., Lahat, E., … Amit, I. (2021). XCR1 + type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nature Medicine, 1–12. https://doi.org/10.1038/s41591-021-01344-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Axcella Announces Initiation of EMMPACT℠ Phase IIb Clinical Trial of AXA1125

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH.
[Axcella, Inc (Business Wire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease

Investigators provide an in-depth discussion of the underlying pathogenetic mechanisms that lead to progressive liver injury, including the metabolic origins of Nonalcoholic fatty liver disease (NAFLD), the effect of NAFLD on hepatic glucose and lipid metabolism, bile acid toxicity, macrophage dysfunction, and hepatic stellate cell activation, and consider the role of genetic, epigenetic, and environmental factors that promote fibrosis progression and risk of hepatocellular carcinoma in nonalcoholic steatohepatitis.
[Cell]
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537–2564. https://doi.org/10.1016/j.cell.2021.04.015 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Regulation and Functional Roles of Chemokines in Liver Diseases

Scientists provide an overview of chemokine biology, with a particular focus on the genetic and epigenetic regulation of chemokine transcription as well as on the cell type-specific production of chemokines by liver cells and liver-associated immune cells.
[Nature Reviews Gastroenterology & Hepatology]
Cao, S., Liu, M., Sehrawat, T. S., & Shah, V. H. (2021). Regulation and functional roles of chemokines in liver diseases. Nature Reviews Gastroenterology & Hepatology, 1–18. https://doi.org/10.1038/s41575-021-00444-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share